Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575 · see citing works

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809 · see citing works

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069 · see citing works

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,063 · see citing works

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,363 · see citing works

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,665 · see citing works

The Novel Coronavirus Originating in Wuhan, China

Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210 · see citing works

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431 · see citing works

SARS Vaccine Development

Jiang, S., He, Y., & Liu, S. (2005) · Emerging infectious diseases · doi:10.3201/1107.050219 · Cited by 215 · see citing works

S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients

Hofmann, H., Hattermann, K., Marzi, A., Gramberg, T., Geier, M., Krumbiegel, M., Kuate, S., Überla, K., Niedrig, M., & Pöhlmann, S. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6134-6142.2004 · Cited by 197 · see citing works

SARS vaccines: where are we?

Roper, R. L., & Rehm, K. E. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.43 · Cited by 179 · see citing works

Current status on the development of pseudoviruses for enveloped viruses

Li, Q., Liu, Q., Huang, W., Li, X., & Wang, Y. (2017) · Reviews in Medical Virology · doi:10.1002/rmv.1963 · Cited by 167 · see citing works

Molecular Basis of Coronavirus Virulence and Vaccine Development

Enjuanes, L., Zúñiga, S., Castaño-Rodríguez, C., Gutierrez-Alvarez, F. J., Cantón, J., & Sola, I. (2016) · Advances in virus research · doi:10.1016/bs.aivir.2016.08.003 · Cited by 158 · see citing works

Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection

Liu, Q., Fan, C., Li, Q., Zhou, S., Huang, W., Wang, L., Sun, C., Wang, M., Wu, X., Ma, J., et al. (2017) · Scientific Reports · doi:10.1038/srep45552 · Cited by 87 · see citing works

The emerging role of systems biology for engineering protein production in CHO cells

Kuo, C., Chiang, A. W. T., Shamie, I., Samoudi, M., Gutierrez, J. M., & Lewis, N. E. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.11.015 · Cited by 80 · see citing works

Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system

Nie, J., Wu, X., Ma, J., Cao, S., Huang, W., Liu, Q., Li, X., Li, Y., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/srep42769 · Cited by 69 · see citing works

Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities

Nie, J., Liu, L., Wang, Q., Chen, R., Ning, T., Liu, Q., Huang, W., & Wang, Y. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1571871 · Cited by 52 · see citing works

A Human DPP4-Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV

Fan, C., Wu, X., Liu, Q., Li, Q., Liu, S., Lu, J., Yang, Y., Cao, Y., Huang, W., Liang, C., et al. (2018) · Viruses · doi:10.3390/v10090448 · Cited by 47 · see citing works

A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system

Zhang, L., Li, Q., Liu, Q., Huang, W., Nie, J., & Wang, Y. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1325050 · Cited by 41 · see citing works

Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells

Chen, Q., Nie, J., Huang, W., Jiao, Y., Li, L., Zhang, T., Zhao, J., Wu, H., & Wang, Y. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1373922 · Cited by 29 · see citing works

In vitroandin vivoefficacy of a Rift Valley fever virus vaccine based on pseudovirus

Ma, J., Chen, R., Huang, W., Nie, J., Liu, Q., Wang, Y., & Yang, X. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1627820 · Cited by 29 · see citing works

An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions

Li, Q., Liu, Q., Huang, W., Wu, J., Nie, J., Wang, M., Zhao, C., Zhang, L., & Wang, Y. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.101 · Cited by 23 · see citing works

Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system

Wu, J., Zhao, C., Liu, Q., Huang, W., & Wang, Y. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.10.007 · Cited by 23 · see citing works

Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus

Nakamura, K., Harada, Y., Takahashi, H., Trusheim, H., Roth, B., Hamamoto, I., Hirata‐Saito, A., Oogane, T., Mizuta, K., Konomi, N., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.08.064 · Cited by 20 · see citing works

HIV-1 pseudoviruses constructed in China regulatory laboratory

Nie, J., Huang, W., Liu, Q., & Wang, Y. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1702479 · Cited by 20 · see citing works

Immunology of COVID-19: Current State of the Science

Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623 · see citing works

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J., Du, P. F., Wei, D., Yang, Z., Sun, X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,592 · see citing works

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504 · see citing works

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420 · see citing works

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253 · see citing works

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · see citing works

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188 · see citing works

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

Tan, C. W., Chia, W. N., Qin, X., Liu, P., Chen, M. I.-C., Tiu, C. K., Hu, Z., Chen, V. C.-W., Young, B. E., Sia, W. R., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0631-z · Cited by 1,162 · see citing works

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ni, L., Ye, F., Cheng, M., Yu, F., Deng, Y., Zhao, H. J., Peng, W., Ge, J., Gou, M., Li, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.023 · Cited by 1,069 · see citing works

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)

Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L. R., Cheng, V. C., Edwards, K. M., Gandhi, R. T., Muller, W. J., O’Horo, J. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa478 · Cited by 1,044 · see citing works

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · see citing works

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Yang, H. J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., Bao, L., Mo, F., Li, X., Huang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2599-8 · Cited by 753 · see citing works

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 727 · see citing works

Antibody tests for identification of current and past infection with SARS‐CoV‐2

Geppert, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., Bergman, H., Buckley, S. B., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 725 · see citing works

COVID-19 neutralizing antibodies predict disease severity and survival

Garcia-Beltran, W., Lam, E., Astudillo, M., Yang, D., Miller, T., Feldman, J., Hauser, B., Caradonna, T. M., Clayton, K., Nitido, A. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 56 · see citing works

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 677 · see citing works

A thermostable mRNA vaccine against COVID-19

Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671 · see citing works

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works

Antibody tests for identification of current and past infection with SARS-CoV-2

Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., di Ruffano, L. F., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 650 · see citing works

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

Yang, L., Han, Y., Nilsson-Payant, B. E., Gupta, V., Wang, P., Duan, X., Tang, X., Zhu, J., Zhao, Z., Jaffré, F., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.06.015 · Cited by 632 · see citing works

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572 · see citing works

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids

Han, Y., Duan, X., Yang, L., Nilsson-Payant, B. E., Wang, P., Duan, F., Tang, X., Yaron, T. M., Zhang, T., Uhl, S., et al. (2021) · Nature · doi:10.1038/s41586-020-2901-9 · Cited by 530 · see citing works

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

Zhao, M., Yang, W., Yang, F., Zhang, L., Huang, W., Hou, W., Fan, C., Jin, R., Feng, Y., Wang, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00558-8 · Cited by 514 · see citing works

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.035 · Cited by 476 · see citing works

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance

Whitman, J. D., Hiatt, J. B., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0659-0 · Cited by 451 · see citing works

Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2

Younes, N., Al‐Sadeq, D. W., Al-Jighefee, H. T., Younes, S. N., Al-Jamal, O., Daas, H. I., Yassine, H. M., & Nasrallah, G. K. (2020) · Viruses · doi:10.3390/v12060582 · Cited by 437 · see citing works

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 418 · see citing works

Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection

Tali, S. H. S., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi‐Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 411 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410 · see citing works

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron

Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.019 · Cited by 406 · see citing works

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 398 · see citing works

Molecular Diagnosis of COVID-19: Challenges and Research Needs

Feng, W., Newbigging, A. M., Le, C., Pang, B., Peng, H., Cao, Y., Wu, J., Abbas, G., Song, J., Wang, D., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02060 · Cited by 387 · see citing works

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Lv, Z., Deng, Y., Ye, Q., Cao, L., Sun, C.-Y., Fan, C., Huang, W., Sun, S., Sun, Y., Zhu, L., et al. (2020) · Science · doi:10.1126/science.abc5881 · Cited by 362 · see citing works

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

Zhang, L., Li, Q., Liang, Z., Li, T., Liu, S., Cui, Q., Nie, J., Wu, Q., Qu, X., Huang, W., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2017757 · Cited by 352 · see citing works

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

To, K. K., Sridhar, S., Chiu, K. H., Hung, D. L. L., Li, X., Hung, I. F., Tam, A. R., Chung, T. W., Chan, J. F., Zhang, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1898291 · Cited by 350 · see citing works

Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management

Anka, A. U., Tahir, M. I., Abubakar, S. D., Alsabbagh, M. Y., Zian, Z., Hamedifar, H., Sabzevari, A., & Azizi, G. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12998 · Cited by 348 · see citing works

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.042 · Cited by 341 · see citing works

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Ai, J., Zhang, H., Zhang, Y., Lin, K., Zhang, Y., Wu, J., Wan, Y., Huang, Y., Song, J., Fu, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2022440 · Cited by 339 · see citing works

COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace

Cirrincione, L., Plescia, F., Ledda, C., Rapisarda, V., Martorana, D., Moldovan, R. E., Theodoridou, K., & Cannizzaro, E. (2020) · Sustainability · doi:10.3390/su12093603 · Cited by 336 · see citing works

Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen

Liu, D., Ju, C., Han, C., Shi, R., Chen, X., Duan, D., Yan, J., & Yan, X. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112817 · Cited by 327 · see citing works

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Muruato, A. E., Fontes-Garfias, C. R., Ren, P., Garcia-Blanco, M. A., Menachery, V. D., Xie, X., & Shi, P.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17892-0 · Cited by 319 · see citing works

The Role of Antibody Testing for SARS-CoV-2: Is There One?

Theel, E. S., Slev, P. R., Wheeler, S., Couturier, M. R., Wong, S. J., & Kadkhoda, K. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00797-20 · Cited by 303 · see citing works

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

Trougakos, I. P., Stamatelopoulos, K. S., Terpos, E., Tsitsilonis, O., Aivalioti, E., Paraskevis, D. N., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 284 · see citing works

The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review

Haghani, M., Bliemer, M. C. J., Goerlandt, F., & Li, J. (2020) · Safety Science · doi:10.1016/j.ssci.2020.104806 · Cited by 266 · see citing works

ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection

Hachim, A., Kavian, N., Cohen, C. A., Chin, A. W. H., Chu, D. K. W., Mok, C. K. P., Tsang, O. T., Yeung, Y. C., Perera, R. A. P. M., Poon, L. L. M., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0773-7 · Cited by 262 · see citing works

Humoral Responses and Serological Assays in SARS-CoV-2 Infections

Galipeau, Y., Greig, M., Liu, G., Driedger, M., & Langlois, M.-A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610688 · Cited by 225 · see citing works

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Du, S., Cao, Y., Zhu, Q.-Y., Yu, P., Qi, F.-F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 249 · see citing works

Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis

Liu, M., Gao, Y., Yuan, Y., Yang, K., Shi, S., Zhang, J., & Tian, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104896 · Cited by 230 · see citing works

COVID-19 Antibody Tests and Their Limitations

Liu, G., & Rusling, J. F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02621 · Cited by 219 · see citing works

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216 · see citing works

SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself

Ferreira‐Gomes, M., Kruglov, A., Durek, P., Heinrich, F., Tizian, C., Heinz, G. A., Reguant, A. P., Du, W., Mothes, R., Fan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22210-3 · Cited by 211 · see citing works

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

Dieterle, M. E., Haslwanter, D., Bortz, R. H., Wirchnianski, A. S., Lasso, G., Vergnolle, O., Abbasi, S. A., Fels, J. M., Laudermilch, E., Florez, C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.020 · Cited by 202 · see citing works

Antibody tests for identification of current and past infection with SARS-CoV-2

Fox, T., Geppert, J., Dinnes, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P. N., Wickramasinghe, D., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652.pub2 · Cited by 200 · see citing works

High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients

Chen, Y., Tong, X., Wang, J., Huang, W., Yin, S., Huang, R., Yang, H., Chen, Y., Huang, A., Liu, Y., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.067 · Cited by 199 · see citing works

Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges

Kiliç, T., Weissleder, R., & Lee, H. (2020) · iScience · doi:10.1016/j.isci.2020.101406 · Cited by 196 · see citing works

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Hu, Y., Meng, X., Zhang, F., Xiang, Y., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1888660 · Cited by 183 · see citing works

Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection

Guo, L., Yao, Z., Yang, L., Zhang, H., Qi, Y., Gou, L., Wang, X., Liu, D., Zhang, L., Cheng, Y., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127742 · Cited by 182 · see citing works

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays

Perkmann, T., Perkmann‐Nagele, N., Köller, T., Mucher, P., Radakovics, A., Marculescu, R., Wolzt, M., Wagner, O. F., Binder, C. J., & Haslacher, H. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00247-21 · Cited by 181 · see citing works

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses

Ladner, J. T., Henson, S. N., Boyle, A. S., Engelbrektson, A. L., Fink, Z., Rahee, F., D’ambrozio, J., Schaecher, K. E., Stone, M., Dong, W., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100189 · Cited by 179 · see citing works

Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

Xu, R., Shi, M., Li, J., Song, P., & Li, N. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00862 · Cited by 176 · see citing works

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

Rockett, R. J., Basile, K., Maddocks, S., Fong, W., Agius, J. E., Johnson-Mackinnon, J., Arnott, A., Chandra, S., Gall, M., Draper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2120219 · Cited by 171 · see citing works

Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75

Cao, Y., Song, W., Wang, L., Liu, P., Yue, C., Jian, F., Yu, Y., Yisimayi, A., Wang, P., Wang, Y., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.09.018 · Cited by 169 · see citing works

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai, R., Zhou, D., Tuekprakhon, A., Ginn, H. M., Supasa, P., Liu, C., Huo, J., Mentzer, A. J., Duyvesteyn, H. M. E., Dijokaite-Guraliuc, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.014 · Cited by 164 · see citing works

V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity

Ou, J., Zhou, Z., Dai, R., Zhang, J., Zhao, S., Wu, X., Lan, W., Ren, Y., Cui, L., Lan, Q., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00617-21 · Cited by 162 · see citing works

Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells

Xiong, H., Wu, Y., Cao, J., Yang, R., Liu, Y., Ma, J., Qiao, X., Yao, X., Zhang, B.-H., Zhang, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1815589 · Cited by 155 · see citing works

Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1

Jian, F., Wang, J., Yisimayi, A., Song, W., Xu, Y., Chen, X., Niu, X., Yang, S., Yu, Y., Wang, P., et al. (2024) · Nature · doi:10.1038/s41586-024-08315-x · Cited by 155 · see citing works

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 152 · see citing works

Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

D'Cruz, R. J., Currier, A. W., & Sampson, V. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00468 · Cited by 151 · see citing works

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Custódio, T. F., Das, H., Sheward, D. J., Hanke, L., Pažický, S., Pieprzyk, J., Sorgenfrei, M., Schroer, M. A., Gruzinov, A. Y., Jeffries, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19204-y · Cited by 151 · see citing works

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Liang, J. G., Su, D., Song, T., Zeng, Y., Huang, W., Wu, J., Xu, R., Luo, P., Yang, X., Zhang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21634-1 · Cited by 151 · see citing works

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1902245 · Cited by 150 · see citing works

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents

Cao, Y., Jian, F., Zhang, Z., Yisimayi, A., Hao, X., Bao, L., Yuan, F., Yu, Y., Du, S., Wang, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111845 · Cited by 149 · see citing works

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

Lu, J., Lu, G., Tan, S., Jia Hui, X. I. A., Xiong, H., Yu, X., Qi, Q., Yu, X., Li, L., Yu, H., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00392-7 · Cited by 147 · see citing works

Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals

Zhang, J., Wu, Q., Liu, Z., Wang, Q., Wu, J., Hu, Y., Bai, T., Xie, T., Huang, M., Wu, T., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00824-5 · Cited by 147 · see citing works

Review of Current COVID-19 Diagnostics and Opportunities for Further Development

Mardian, Y., Kosasih, H., Karyana, M., Neal, A., & Lau, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615099 · Cited by 147 · see citing works

High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening

Clarke, C., Prendecki, M. F., Dhutia, A., Ali, M. A., Sajjad, H., Shivakumar, O., Lightstone, L., Kelleher, P., Pickering, M. C., Thomas, D., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020060827 · Cited by 145 · see citing works

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

Cao, Y., Yisimayi, A., Bai, Y., Huang, W., Li, X., Zhang, Z., Yuan, T., An, R., Wang, J., Xiao, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00514-9 · Cited by 140 · see citing works

Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2

Jang, Y., Shin, H., Lee, M. K., Kwon, O. S., Shin, J. S., Kim, Y., Kim, C. W., Lee, H.-R., & Kim, M. (2021) · Scientific Reports · doi:10.1038/s41598-020-80896-9 · Cited by 136 · see citing works

Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2

Cheng, M. P., Yansouni, C. P., Basta, N. E., Desjardins, M., Kanjilal, S., Paquette, K., Caya, C., Semret, M., Quach, C., Libman, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2854 · Cited by 134 · see citing works

High neutralizing antibody titer in intensive care unit patients with COVID-19

Liu, L., To, K. K., Chan, K., Wong, M. Y.-C., Zhou, R., Kwan, K., Fong, C. H.-Y., Chen, L., Choi, C. Y.-K., Lu, L., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1791738 · Cited by 132 · see citing works

SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus

Dogan, M., Kozhaya, L., Placek, L., Gunter, C., Yi̇ği̇t, M., Hardy, R., Plassmeyer, M., Coatney, P., Lillard, K., Bukhari, Z., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01649-6 · Cited by 95 · see citing works

SARS-CoV-2 infection causes dopaminergic neuron senescence

Chen, S., Kim, T. W., Yang, L., Kim, T., Nair, M., Harschnitz, O., Wang, P., Zhu, J., Koo, S. Y., Tang, X., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2023.12.012 · Cited by 124 · see citing works

Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients

Yu, Y.-L., Wang, M., Zhang, X.-A., Li, S.-F., Lu, Q.-Y., Zeng, H.-L., Hou, H., Li, H., Zhang, M.-Y., Jiang, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00759-1 · Cited by 108 · see citing works

Comparison of Four SARS-CoV-2 Neutralization Assays

Riepler, L., Rössler, A., Falch, A., Volland, A., Borena, W., von Laer, D., & Kimpel, J. (2020) · Vaccines · doi:10.3390/vaccines9010013 · Cited by 117 · see citing works

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsPreprint

Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.30.442182 · Cited by 117 · see citing works

A comparative review of immunoassays for COVID-19 detection

Mohit, E., Rostami, Z., & Vahidi, H. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908886 · Cited by 116 · see citing works

Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates

Shou, S., Liu, M., Yang, Y., Kang, N., Song, Y., Tan, D., Liu, N.-N., Wang, F., Liu, J., & Xie, Y.-H. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.626553 · Cited by 112 · see citing works

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

Khoury, D. S., Wheatley, A. K., Ramuta, M. D., Reynaldi, A., Cromer, D., Subbarao, K., O’Connor, D. H., Kent, S. J., & Davenport, M. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00471-1 · Cited by 115 · see citing works

25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor

Zu, S., Deng, Y., Chao Hui, Z. H. O. U., Li, J., Li, L., Chen, Q., Li, X., Zhao, H. J., Gold, S., He, J., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00398-1 · Cited by 115 · see citing works

ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species

Yan, H., Jiao, H., Liu, Q., Zhang, Z., Xiong, Q., Wang, B.-J., Wang, X., Guo, M. S., Wang, L., Lan, K., et al. (2021) · Nature Ecology & Evolution · doi:10.1038/s41559-021-01407-1 · Cited by 115 · see citing works

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021) · doi:10.1101/2021.02.05.430003 · Cited by 153 · see citing works

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

Hu, Y., Ma, C., Szeto, T., Hurst, B. L., Tarbet, E. B., & Wang, J. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00761 · Cited by 112 · see citing works

Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung OrganoidsPreprint

Han, Y., Yang, L., Duan, X., Duan, F., Nilsson-Payant, B. E., Yaron, T. M., Wang, P., Tang, X., Zhang, T., Zhao, Z., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.05.079095 · Cited by 107 · see citing works

Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification

Li, X., Zhu, W., Fan, M., Zhang, J., Peng, Y., Huang, F., Wang, N., He, L., Zhang, L., Holmdahl, R., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.001 · Cited by 105 · see citing works

Construction and applications of SARS-CoV-2 pseudoviruses: a mini review

Chen, M., & Zhang, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59184 · Cited by 104 · see citing works

A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients

Chen, Y., Tong, X., Li, Y., Gu, B., Yan, J., Liu, Y., Shen, H., Huang, R., & Wu, C. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008796 · Cited by 103 · see citing works

On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies

Mattioli, I. A., Hassan, A., Oliveira, O. N., & Crespilho, F. N. (2020) · ACS Sensors · doi:10.1021/acssensors.0c01382 · Cited by 102 · see citing works

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 418 · see citing works

Detection of Neutralizing Antibodies in Serum Samples Using a SARS‐CoV‐2 Pseudotyped Virus Assay

Ferrero, S., Batto, M. V., Gatto, M. I., Dimase, F., & Helguera, G. F. (2024) · Current Protocols · doi:10.1002/cpz1.70025

Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay

Tolah, A. M., Sohrab, S. S., Tolah, K. M., Hassan, A. M., El-Kafrawy, S. A., & Azhar, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11060994 · Cited by 33 · see citing works

Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hassannia, H., Enderami, S. E., Mansour, R. N., Eftekhary, M., Abazari, M., & Salarinia, R. (2023) · DOAJ (DOAJ: Directory of Open Access Journals)

Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2

Balinsky, C. A., Jani, V., Sun, P., Williams, M., Defang, G. N., & Porter, K. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_21 · Cited by 5 · see citing works